On Friday 29th July 2016, Celgene, Stockley Park, UK Celgene announce that REVLIMID® (lenalidomide), in combination with low-dose dexamethasone, has been recommended by the All Wales Medicine Strategy Group (AWMSG) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM), who are not eligible for transplant and are unsuitable for thalidomide-containing regimens. This recommendation enables NHS access to the treatment combination for eligible Welsh patients, joining patients in Scotland and Northern Ireland who currently have access to the combination in this…